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The log/linear relation between serum thyrotropin (TSH) and free thyroxine (FT 4 ) makes TSH, when measured by a highly sensitive method, a more sensitive indicator of thyroid disfunction than FT 4 [1] .
Nonisotopic immunometric assays are the methods of choice to measure serum TSH, as they are at least equally sensitive to IRMAs, can be automated, are generally faster and more convenient than IRMAs, and do not use radioisotopes. Within the former group of methods, the immunochemiluminometric assay is increasingly popular because of its inherent sensitivity, but instrumental and triggering modes may jeopardize it. A new immunoelectrochemiluminometric assay (IECMA) has recently come on the market [2] . It is based on electrogenerated chemiluminescence that, aiming to avoid the instability of luminophores, does not proceed in free solution but on to the surface of a platinum electrode [3, 4] . We describe the evaluation of such a method using the random access analyzer Elecsys ® 2010 (Boehringer Mannheim Diagnostics).
The method consists of two immunological "sandwich" reactions linking, at one side, sample TSH to a solid phase of paramagnetic streptavidin-coated microparticles by means of a biotinylated monoclonal TSH-specific antibody and, at the other side, a Ru-labeled TSH-specific antibody. Separation of bound and unbound TSH is made by a magnet, and luminescence from a luminophore is triggered electrochemically.
The immunological reaction consists of a first incubation where 50 L of sample, the biotinylated antibody, and the Ru-labeled antibody react for 9 min, when antibodies capture the TSH present in the sample to form a sandwich complex. In a second step, streptavidin-coated paramagnetic microparticles are added, and during a second 9-min incubation time the biotinylated antibody attaches to the streptavidin-coated surface of the microparticles. The reaction mixture containing the immune complex, with the sample TSH linked to the microparticles, is then aspirated into a measuring cell, and is magnetically captured on the surface of a platinum electrode. Unbound substances are washed away by a buffer that at the same time provides tripropylamine (TPA), an electrochemically active substance.
The chemiluminescence reaction that leads to the emission of light results from the interaction of TPA and the Ru complex (containing the sample TSH) at the surface of the electrode [4] . Both substances remain stable until application of voltage creates an electric field, which starts the reaction. This consists of an electrochemical oxidation of both luminophore and amine. The oxidation product of TPA produces an unstable, highly reducing intermediate. The oxidized luminophore Ru(2-2Ј-bipyridine) 3 3ϩ accepts an electron from the deprotonated TPA radical, leading to an excited state of the former and to an ultimate emission of photons at 620 nm. Light emission is directly proportional to the Ru concentration and, consequently, to the TSH concentration in the sample. The Ru ground state is generated many times and therefore multiple light generation cycles are performed during the measuring process, with parallel gain in sensitivity. Concentrations of TSH are calculated from a calibration curve generated by a two-point calibration (0.00 and 1.30 mU/L), and a master curve is provided via the reagent bar code. The makers state that the calibrators were recalibrated against the 2nd IRP WHO Reference Standard 80/558.
The Elecsys 2010 Immunoassay System has a control unit and an analyzer unit. The latter consists of three areas: sample/reagent, consumables, and measuring. The sample/reagent area consists of a sample disk with 18 positions for a maximum of 15 analytes, a sample/reagent pipettor, and a bar-code reader. The measuring area consists of a 32-position incubator (37°C) and a sipper probe, which aspirates the reaction mixture, buffer, and cleaning fluid through the measuring cell and is washed externally by means of a sipper rinse station; the detection unit contains a photomultiplier, a peltier system, a flowthrough measuring cell, a magnet drive assembly, and an amplifier. The control unit consists of a touch-screen monitor, a keyboard, and a floppy disk drive. The Elecsys 2010 Manual, Boehringer Mannheim, May 1996, fully describes the above equipment. Results below the stated detection limit (0.005 mU/L) are reported as Ͻ0.005 mU/L. Throughout our evaluation we strictly adhered to the manufacturer specifications (Elecsys TSH Immunoassay, Boehringer Mannheim, Nov. 1996).
To determine intraassay imprecision, 21 replicates of serum pools of 0.07, 2.09, and 61.4 mU/L TSH gave CVs of 2.5%, 2.1%, and 1.1%, respectively. For interassay imprecision 21 determinations done on different days on commercial control sera (PreciControl, Boehringer Mannheim) of 0.24, 2.03, 9.15, and 67 mU/L gave CVs of 3.3%, 3.6%, 3.3%, and 2.5%, respectively.
To estimate functional sensitivity [5] , 20 assays were done on successive working days during 4 weeks on sera with 0.024 and 0.0098 mU/L, and gave CVs of 7.4% and 16.5%, respectively. Only the first lot of reagents (no. 191375) and calibrators is available at present, so the sound suggestion of Spencer et al. [5] for assessing functional sensitivity with several lots had to be postponed.
To assess carryover we followed the protocol of the ECCLS [6] and used two serum pools of 91 mU/L (high) and 0.012 mU/L (low), with a high:low TSH ratio of Ͼ7500:1. We measured three consecutive samples of the high-concentration pool (H), followed by three of the low-concentration pool (L), and this sequence was repeated five times. The percentage carryover was calculated according to the equation: carryover % ϭ [(L 1 Ϫ L 3 )/(H 3 Ϫ L 3 )] ϫ 100 [7] . Carryover was found to be 0.002%, which is below the maximum of 0.01% suggested by Sadler et al. [8] for a third-generation assay.
For linearity a serum with 45.8 mU/L TSH was diluted 1:2, 1:5, 1:10, and 1:25 with "TSH Universal Diluent" (the measured concentration of which, 0.014 mU/L TSH, was accounted for). For low concentrations a serum with 1.26 mU/L TSH was equally diluted with the 0.00 mU/L TSH calibrator. Regression lines and maximum deviations (%) of the obtained points from the correlative points on the regression lines were, respectively, y ϭ 1.05x Ϫ 0.13 (4.8%) at the upper interval, and y ϭ 0.99x ϩ 0.0007 (0.6%) at the lower interval.
Mean deviation from target values of PreciControl TSH 0.24 mU/L, and PreciControl Universal TSH 2.06 and 9.50 mU/L (Boehringer Mannheim) were respectively 1.2%, 1.1%, and 3.7%. The method was compared with the TSH Abbott IMx microparticle enzyme immunoassay (MEIA) method, with a stated functional sensitivity of 0.04 mU/L. Accordingly, the 30 paired samples were chosen with TSH values above that and not aiming to countercheck sensitivity. Measuring range was 0.045-62.7 mU/L with a mean of 8.3. y Ϫ x was 0.93 mU/L, r ϭ 0.996 and, according to Passing and Bablok [9] , the intercept was 0.058 mU/L and the slope 1.13. (Scatter diagram is shown in Fig. 1 .) When only 11 samples with values ranging 0.045 to 0.71 mU/L were compared, the intercept was 0.01 mU/L and the slope 1.27.
The minimum sample volume requirement was 150 L.
Regarding speed, once analyses began, the first result was printed in 18 min, and subsequent results came out every 40 s (100 tests in 1 h and 24 min). Ground noise level was 60 dB with occasional peaks of 70 dB as measured with a sound level meter type 2219 (Brü el og Kjaer).
To obtain interim reference values, sera from 32 healthy blood donors (16 women and 16 men, each sex 20 to 60 years of age) were analyzed. After logarithmic transformation [1] , mean Ϯ 2 SD range was 0.43 to 3.65 mU/L.
In a preliminary clinical study we aimed to assess cases with TSH Յ0.005 mU/L and to distinguish endocrine hyperactivity from other situations. Thirty of 38 cases proved to have clinical thyroid hyperactivity-some due to amiodarone treatment-with increased serum thyroid hormones concurrently, or in the last few months, with those profoundly low TSH concentrations. One case had panhypopituitarism, and in the remaining seven, hyperactivity could not, so far, be proved. This is in accord with the statement that clinical overt hyperthyroidism is generally associated with TSH Ͻ0.005 mU/L [1] .
We conclude that this new assay to measure TSH has an imprecision and a functional sensitivity of the thirdgeneration methods that can distinguish active hyperthyroidism from nonthyroideal diseases, in accordance with the recommendations of the American Thyroid Association [5, 10] . Large and small batches are conveniently analyzed and the low imprecision permits singleton analyses.
We thank Boehringer Mannheim, Barcelona, Spain, for two kits of reagents free of charge. The group of tumor-associated antigens with superficial carbohydrate structure influencing cell-cell interaction processes and cell growth regulation is commonly named "mucins," characterized by large and heterogeneic molecular mass and the presence of O-linked carbohydrates. Mucins are released in extracellular space and can be found and measured in serum and other biological fluids. Among mucins, CA 19.9 is widely used for diagnosing gastrointestinal cancers [1] , CA 125 for gynecological cancers [2] , and CA 15.3 for breast cancer [3] . Despite the wide use of these tumor markers in clinical laboratories, few data about their preanalytical phase exist.
We studied the stability of CA19.9, CA 125, and CA 15.3 for 72 h and the effect of serum collection differences between plain tubes and tubes with thixotropic gel. We used our findings to define practical and empirical guidelines for blood drawing, storage, transportation, and delay from venipuncture to analysis.
We collected blood by routine sampling, namely, in plain tubes (pink cap, 7-mL Vacutainer Tube; Becton Dickinson) and in gel-containing tubes (gold cap, 5-mL Vacutainer Tube), completely filling the tubes and centrifuging them at 4°C for 10 min at 1560g. The samples were stored at room temperature until analyses (within 3 h from blood drawing) and afterwards at 4°C.
We collected 20 pairs of samples in plain and gelcontaining tubes for each of the three markers from outpatients who had already had one or more measurements in our laboratory for the marker in the previous 2 months. This way, we obtained values opportunely and regularly distributed in the linearity range of the method: 0 -240 IU/mL for CA 19.9, 0 -200 IU/mL for CA 15.3, and 0 -500 IU/mL for CA 125.
For ethical reasons, only patients with a physician's request for a tumor marker (routinely assayed in plain tubes) and general clinical chemistry (routinely assayed in gel-containing tubes) tests were recruited. CA 19.9, CA 125, and CA 15.3 were measured by the same operator with the automated system Immuno1 (Bayer) by immunoenzymometric methods. The tumor marker assays were also performed on the contents of 5 separator-gel tubes filled with doubly distilled water and 5 tubes filled with serum containing no immunoassayable mucins; these measurements were performed after 72 h of contact between liquids and gels. The results were evaluated statistically by using Student's paired t-test, with P Ͻ0.05 considered as significant.
We noted a conspicuous increase of the measured markers in the gel-containing tubes after 24 h ( Table 1) .
The stability is an important finding for mucins because some laboratories do not perform these analyses but send the sample in tubes to other centers, and some laboratories that do perform the measurements do not perform them daily.
The gel-containing tubes are widely used for endocri- 
